Skip to main content

Table 1 Blood data at admission, during antibody cocktail therapy, and before discharge

From: Safety of casirivimab/imdevimab administration in a SARS-CoV-2 positive maintenance dialysis patient in Japan

  Day 0 Day 2 (antibody cocktail was administered) Day 7 Reference range
White blood cell (/μl) 3710 2750 3180 3200–7900
Hemoglobin (g/dl) 11.7 10.9 10.9 11.3–15.0
Platelet (× 103/μL) 160 131 148 155–350
Albumin (g/dL) 4,0 3.5 3.6 4.1–5.1
Total bilirubin 0.3 0.3 0.4 0.3–11
Blood urea nitrogen (mg/dL) 32.6 22.5 40.5 8–21
Creatinine (mg/dL) 13.33 10.84 14.59 0.6–1.0
C-reactive protein (CRP) 2.24 1.77 0.62 < 0.3
Sodium (mEq/L) 144 143 141 138–145
Chloride (mEq/L) 107 106 103 101–108
Potassium (mEq/L) 3.8 3.7 4.3 3.6–4.8
Aspartate aminotransferase (IU/l) 16 15 14 11–38
Alanine transaminase (IU/l) 9 8 10 6–50
Lactate dehydrogenase (IU/l) 156 138 173 103–190
Glucose (mg/dL) 87 81 81 73 − 109
Hemoglobin A1c (%) 4.1    4.9–6.0
PT-INR 1.02 1.00 1.04 0.90–1.10
APTT (sec) 28 29 31 25–35
Fib (mg/dL) 354 334 317 200–400
d-Dimer (μg/mL) 1.4 1.7 2.9 0.0–1.0
  1. Hemodialysis was performed on day 1, 2, 5, 7. Blood samples were taken before dialysis